{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:55Z","timestamp":1791111355652,"version":"4.1.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:sec id=\"ab-doi240022-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi240022-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi240022-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi240022-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi240022-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi240022-9\">\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.2056","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T11:00:44Z","timestamp":1721214044000},"page":"927","source":"Crossref","is-referenced-by-count":27,"title":["Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation"],"prefix":"10.1001","volume":"160","author":[{"given":"Reineke","family":"Soegiharto","sequence":"first","affiliation":[{"name":"Department of Dermatology\/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Alizadeh Aghdam","sequence":"additional","affiliation":[{"name":"Department of Dermatology\/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Astrup","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology and Wound Healing Centre, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"van Lindonk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus MC, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhan","family":"Bulut Demir","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Marmara University School of Medicine, Fevzi Cakmak Mah, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser Mohammad","family":"Porras","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar-Institut d\u2019Investigacions M\u00e8diques Universitat Pompeu Fabra de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charit\u00e9, Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 C.","family":"Knulst","sequence":"additional","affiliation":[{"name":"Department of Dermatology\/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[{"name":"Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charit\u00e9, Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Secciones Alergia Adultos y Pedi\u00e1trica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rudenko","sequence":"additional","affiliation":[{"name":"London Allergy and Immunology Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emek","family":"Kocat\u00fcrk","sequence":"additional","affiliation":[{"name":"Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charit\u00e9, Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Department of Dermatology, Ko\u00e7 University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta F. J.","family":"Criado","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculdade de Medicina do ABC, Bairro Sacadura Cabral, Santo Andr\u00e9, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatis","family":"Gregoriou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology and Venereology, National and Kapodistrian University of Athens A Syggros Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Bobylev","sequence":"additional","affiliation":[{"name":"Clinic for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kleinheinz","sequence":"additional","affiliation":[{"name":"Clinic for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Takahagi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"},{"name":"Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Naka-ku, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar-Institut d\u2019Investigacions M\u00e8diques Universitat Pompeu Fabra de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda\u00e7","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Marmara University School of Medicine, Fevzi Cakmak Mah, \u0130stanbul, Turkey"},{"name":"Department of Dermatology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia O.","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sakarya University Faculty of Medicine, Korucuk, Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Sevimli Dikicier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sakarya University Faculty of Medicine, Korucuk, Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus MC, Netherlands"},{"name":"Centre for Human Drug Research, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology and Wound Healing Centre, University of Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juul M. P. A.","family":"van den Reek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"R\u00f6ckmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology\/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi240022r1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"doi240022r2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","article-title":"Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review.","volume":"12","author":"Balp","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"doi240022r3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"doi240022r4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials.","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"doi240022r5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15928","article-title":"Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: a systematic review and meta-analysis.","volume":"35","author":"He","year":"2022","journal-title":"Dermatol Ther"},{"issue":"1","key":"doi240022r6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy.","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi240022r7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi240022r8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.","volume":"140","author":"Metz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"doi240022r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls.","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"doi240022r10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ad.2017.03.012","article-title":"Comment on \"Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis\".","volume":"108","author":"van den Reek","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"doi240022r11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/all.13714","article-title":"Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.","volume":"74","author":"Spekhorst","year":"2019","journal-title":"Allergy"},{"issue":"12","key":"doi240022r13","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.jaip.2023.08.033","article-title":"Omalizumab drug survival in chronic urticaria: a retrospective multicentric French study.","volume":"11","author":"Litovsky","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"doi240022r14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/pai.13426","article-title":"Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.","volume":"32","author":"Dekkers","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"doi240022r16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1684\/ejd.2017.3085","article-title":"Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.","volume":"27","author":"Ferrer","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"5","key":"doi240022r17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2500\/aap.2015.36.3873","article-title":"The minimal important difference for measures of urticaria disease activity: updated findings.","volume":"36","author":"Mathias","year":"2015","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"doi240022r18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jaci.2017.04.050","article-title":"Responsiveness and minimal important difference of the urticaria control test.","volume":"140","author":"Ohanyan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi240022r19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria.","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi240022r20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11121-007-0070-9","article-title":"How many imputations are really needed\u2014some practical clarifications of multiple imputation theory.","volume":"8","author":"Graham","year":"2007","journal-title":"Prev Sci"},{"issue":"4","key":"doi240022r21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/10705510802339072","article-title":"What improves with increased missing data imputations.","volume":"15","author":"Bodner","year":"2008","journal-title":"Struct Equ Modeling"},{"issue":"1","key":"doi240022r22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.alit.2018.05.011","article-title":"Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study.","volume":"68","author":"Eun","year":"2019","journal-title":"Allergol Int"},{"issue":"5","key":"doi240022r23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1346-8138.2007.00276.x","article-title":"Chronic idiopathic urticaria: prevalence and clinical course.","volume":"34","author":"Kulthanan","year":"2007","journal-title":"J Dermatol"},{"issue":"8","key":"doi240022r24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"issue":"3","key":"doi240022r25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1067\/mjd.2001.116217","article-title":"Natural course of physical and chronic urticaria and angioedema in 220 patients.","volume":"45","author":"Kozel","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi240022r28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2133.2002.04582.x","article-title":"The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre.","volume":"146","author":"van der Valk","year":"2002","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi240022r29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria.","volume":"31","author":"S\u00e1nchez-Borges","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi240022r30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2340\/00015555-2941","article-title":"Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment.","volume":"98","author":"Curto-Barredo","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi240022r31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"doi240022r32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.anai.2018.06.014","article-title":"Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response.","volume":"121","author":"Nettis","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"doi240022r33","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa.","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"doi240022r12","doi-asserted-by":"crossref","unstructured":"Ke? X, Kavati? A, Wertz? D, . Real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the United States.? J Manag Care Spec Pharm. 2018;24(7):598-606. doi:10.18553\/jmcp.2018.24.7.598","DOI":"10.18553\/jmcp.2018.24.7.598"},{"key":"doi240022r15","unstructured":"Global Allergy and Asthma Excellence Network. Urticaria Centers of Reference and Excellence. Accessed April 13, 2023. https:\/\/ga2len-ucare.com\/"},{"key":"doi240022r26","doi-asserted-by":"crossref","unstructured":"Humphreys? F, Hunter? JAA, Humphreys? F. The Characteristics of Urticaria in 390 Patients. Vol 138.; 1998. https:\/\/academic.oup.com\/bjd\/article-abstract\/138\/4\/635\/6683018?redirectedFrom=fulltext","DOI":"10.1046\/j.1365-2133.1998.02175.x"},{"key":"doi240022r27","doi-asserted-by":"crossref","unstructured":"Juhlin? L. Clinical Ami Laboratory Investigations Recurrent Urticaria: Clinical Investigation of 330 Patients. Vol 104.; 1981. https:\/\/academic.oup.com\/bjd\/article-abstract\/104\/4\/369\/6688772?redirectedFrom=fulltext","DOI":"10.1111\/j.1365-2133.1981.tb15306.x"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2821286\/jamadermatology_soegiharto_2024_oi_240022_1729025172.46709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:07:49Z","timestamp":1729076869000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2821286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2056","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}